Author

Angela Gueli

Observed names: A Gueli, A. Gueli, GUELI, ANGELA

Observed institutions: University of Milan, A. O. Ordine Mauriziano di Torino, IRCCS Ospedale San Raffaele, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Turin, European Institute of Oncology

ORCID: 0000-0003-3674-109X

Observed ORCID: 0000-0003-3674-109X

OpenAlex ID: A5005956018

Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma

2010 · Corrado Tarella, Roberto Passera, et al. · Journal of Clinical Oncology · 167

PDF

The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy

2013 · Alessandro Rambaldi, Cristina Boschini, et al. · American Journal of Hematology · 64

PDF

Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma

2015 · A. Balbo-Mussetto, S. Cirillo, et al. · Clinical Radiology · 37

Lymphocyte transformation and autoimmune disorders

2012 · C. Tarella, A. Gueli, et al. · Autoimmunity Reviews · 30

Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival

2014 · Corrado Tarella, Angela Gueli, et al. · PLoS ONE · 26

PDF

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma

2013 · Simone Ferrero, Luigia Monitillo, et al. · Annals of Hematology · 20

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

2019 · Riccardo Bruna, Fabio Benedetti, et al. · Haematologica · 19

PDF

Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis

2014 · M Magni, M Di Nicola, et al. · Bone Marrow Transplantation · 12

Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report.

2013 · Angela Gueli, Daniela Gottardi, et al. · Europe PMC (PubMed Central) · 12

Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia

2012 · Piera Sivera, Marco Ruella, et al. · Blood Coagulation & Fibrinolysis · 7

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

2015 · Corrado Tarella, Angela Gueli, et al. · Blood · 4

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

2013 · Corrado Tarella, Fabio Benedetti, et al. · Blood · 4

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

2012 · Alessandro Rambaldi, Cristina Boschini, et al. · Blood · 3

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

2016 · Enrico Derenzini, Angela Gueli, et al. · Blood · 1

Normal Circulating B Cells Are Markedly Reduced in Follicular Lymphoma and Diffuse Large B Cell Lymphoma at Diagnosis

2014 · Massimo Geuna, Bruna Riccardo, et al. · Blood · 1

Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients.

2009 · Corrado Tarella, Roberto Passera, et al. · Blood · 1

Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin Schedule (DHAP or Ox-DHA) Is Effective and Widely Applicable in Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia.

2009 · Marco Ruella, Irene Ricca, et al. · Blood · 1

Non-Hodgkin’s Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients.

2007 · Angela Gueli, Daniele Caracciolo, et al. · Blood · 1

Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients

2022 · Enrico Derenzini, Angela Gueli, et al. · Hematological Oncology

PDF

Updated 13 Yr Follow-Up of the GITMO-IIL Trial Comparing Upfront R-HDS with Autograft vs. CHOP-R in High-Risk Follicular Lymphoma: Prolonged Survival in Both Arms and a High Rate of Long-Term Disease Free Survivors

2018 · Riccardo Bruna, Fabio Benedetti, et al. · SSRN Electronic Journal

Lymphoproliferative Disorders Associated with Sjögren Syndrome

2016 · Corrado Tarella, Safaa Ramadan, et al. · Rare diseases of the immune system

Surveillance of aggressive lymphoma recurrence after therapy with whole body-MR-DWI: report of a single-centre experience

2015 · Alessandro Mussetto, Alberto Fornari, et al.

Whole Body Magnetic Resonance Imaging with Diffusion Weighted Imaging Is a Valuable Alternative to Contrast-Enhanced Computed Tomography for the Initial Staging in Hodgkin’s and Non-Hodgkin’s Lymphoma

2014 · Annalisa Balbo-Musetto, Riccardo Bruna, et al. · Blood

Long-term results of the phase III GITMO/FIL trial of CHOP-R versus R-HDS plus autograft in high-risk follicular lymphoma (FL) at diagnosis.

2014 · Corrado Tarella, Fabio Benedetti, et al. · Journal of Clinical Oncology

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy

2013 · Rambaldi A, Boschini C, et al. · Institutional Research Information System University of Turin (University of Turin)

Works count: 33

Citation count: 410

H-index: 9

I10-index: 9